Verastem (VSTM) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.72
- Estimate
- -$0.44
- Surprise
- -63.6%
- Revenue (period 2026-09-30)
- $24.0M
- Score today
- 5.9/10
Revenue source: xbrl.
How the report landed
Verastem (VSTM) reported a wider loss than forecast — adjusted EPS of -$0.72 against the -$0.44 estimate (a 63.6% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates VSTM Sell at 5.9/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's -63.6% surprise compares with a -4.4% four-quarter average. Next scheduled report: 2027-03-03.
What argues against it
- Concentration risk — Product: AVMAPKI FAKZYNJA CO-PACK
- Risk below floor (2.3 < 2.5)
- Momentum score 3.7/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $8.41
- Price target
- $14.89
- Stop
- $7.82
- Upside to target
- +77.1%
- Reward-to-risk
- 5.1:1
Model outputs from TrendMatrix’s engine as of 2026-11-07 — shown for context, not personalized investment advice.
VSTM at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.02B
- P/E (fwd)
- -6.9
- 52-week range
- $3.43–$10.82
- Off 52-week high
- 22.3%
- RSI (14)
- 48
- Volume vs avg
- 1.20×
- Score today
- 5.9/10